^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CD14 (CD14 Molecule)

    i
    Other names: CD14, CD14 Molecule, Myeloid Cell-Specific Leucine-Rich Glycoprotein, Monocyte Differentiation Antigen CD14, CD14 Antigen
    1d
    Reprogramming anti-tumor immunity through both NLRP3 inflammasome and cGAS-STING pathways by chiral nanoadjuvants. (PubMed, Sci Bull (Beijing))
    L-Vac demonstrates high in vivo biosafety, breaking down into manganese ions that are primarily excreted through feces. Therefore, chiral adjuvants will pave a brilliant avenue to facilitate cancer immunotherapy.
    Journal • IO biomarker
    |
    STING (stimulator of interferon response cGAMP interactor 1) • CD14 (CD14 Molecule) • CCL2 (Chemokine (C-C motif) ligand 2) • TLR4 (Toll Like Receptor 4) • CCL22 (C-C Motif Chemokine Ligand 22) • CGAS (Cyclic GMP-AMP Synthase) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    5d
    Role of Chitinase 3-like-1 in Myelofibrosis via Fibroblast-Produced Extracellular Matrix Enhancement. (PubMed, J Cell Physiol)
    Romiplostim-induced MF in a mouse model demonstrated extensive bone marrow (BM) CHI3L1 mRNA expression, which was reversed by clodronate treatment. A culture assay revealed that high CHI3L1 concentrations promoted extracellular matrix production by fibroblast cell lines, and that a CHI3L1-neutralizing antibody abrogated this effect. These results indicate the importance of CHI3L1 in the association between fibrocytes and fibroblasts in MF and could be a focus for future treatment.
    Journal
    |
    JAK2 (Janus kinase 2) • CD14 (CD14 Molecule) • CHI3L1 (Chitinase 3-like 1)
    |
    clodronate disodium • Nplate (romiplostim)
    5d
    Computational phosphoproteomic insights into predominant BRAF phosphosites and associated regulatory networks in cancer. (PubMed, Biochim Biophys Acta Proteins Proteom)
    These co-regulated proteins highlight the integration of BRAF signaling with critical processes, such as cell cycle control, apoptosis, DNA damage response, and protein synthesis in melanoma. Our analysis suggests that targeting BRAF-interacting proteins may also modulate oncogenic signaling pathways and represent promising biomarkers for melanoma diagnosis and therapy.
    Journal
    |
    BRAF (B-raf proto-oncogene) • NPM1 (Nucleophosmin 1) • RB1 (RB Transcriptional Corepressor 1) • CHEK2 (Checkpoint kinase 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD14 (CD14 Molecule) • CDK14 (Cyclin Dependent Kinase 14) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • TP53BP1 (Tumor Protein P53 Binding Protein 1) • EIF6 (Eukaryotic Translation Initiation Factor 6)
    |
    BRAF mutation
    5d
    Bispecific Mini-Antibody with an Anti-CD14 Module Effectively Controls Bioavailability of the Human Tumor Necrosis Factor Produced by Human Monocytes. (PubMed, Biochemistry (Mosc))
    In this study, a novel bispecific mini-antibody featuring modules targeting human TNF and CD14 demonstrated efficacy in controlling TNF secretion from human peripheral blood monocytes. Administration of this antibody protected humanized TNF mice from lethal hepatotoxicity induced by a combination of LPS and D-galactosamine.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD14 (CD14 Molecule)
    8d
    Prognostic biomarkers related to PANoptosis in esophageal cancer and their immune microenvironment: multi-omics analysis and therapeutic significance. (PubMed, Front Oncol)
    The CCT6A targeted by the traditional Chinese medicine component quercetin may inhibit PANoptosis by promoting the differentiation of Mono-CD14 cells into TAM-SPP1 macrophages. We constructed prognostic and diagnostic models using PANoptosis-related prognostic biomarkers, analyzed the differences and treatments between high-risk and low-risk groups, and revealed a new mechanism by which CCT6A may inhibit PANoptosis by promoting TAM-SPP1 differentiation, providing new targets and biomarkers for ESCA treatment.
    Journal • IO biomarker
    |
    SPP1 (Secreted Phosphoprotein 1) • CD14 (CD14 Molecule)
    9d
    Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma. (PubMed, Haematologica)
    Both BCMA and CD307e were more highly expressed on BM plasma-cells than CTPCs. This study is among the first to provide a comprehensive phenotypic characterisation of CD56+ CTPCs across the MM spectrum, including checkpoint and chemokine receptors, treated disease cases, and paired BM samples for NDMM.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2RA (Interleukin 2 receptor, alpha) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD69 (CD69 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CCR7 (Chemokine (C-C motif) receptor 7) • CD14 (CD14 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CCR6 (C-C Motif Chemokine Receptor 6) • HLA-C (Major Histocompatibility Complex, Class I, C) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    9d
    Molecular profiling of sacral chordomas through methylation, spatial transcriptomics and multiplexed immunofluorescence. (PubMed, ESMO Rare Cancers)
    Stromal myeloid cells showed increased CD47 and PD-1 expression. Our study identified distinct epigenetic profiles in sacral chordomas, which were associated with recurrence, and revealed expression of checkpoint markers TIM3, CD47 and PD-1, warranting further investigation through functional validation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CD47 (CD47 Molecule) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD14 (CD14 Molecule)
    10d
    Mass cytometry uncovers distinct blood myeloid phenotypes linked to clinical responses during gastric cancer chemoimmunotherapy. (PubMed, Cancer Immunol Immunother)
    We aimed to explore circulating immune cells and elucidate the mechanisms underlying the therapeutic effects of pembrolizumab and capecitabine/oxaliplatin (XELOX) in patients with metastatic GC. Our results elucidate the serial immunological landscape underpinning favorable responses to first-line ICI plus chemotherapy in patients with gastric cancer. Early distinct changes in blood myeloid cells during chemotherapy can be used to assess clinical response.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • NCAM1 (Neural cell adhesion molecule 1) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • CCL3 (C-C Motif Chemokine Ligand 3) • ITGAX (Integrin Subunit Alpha X)
    |
    Keytruda (pembrolizumab) • capecitabine • oxaliplatin
    10d
    Detection of Cytomegalovirus in Patients Attending a Tertiary Care Center: A Retrospective Analysis. (PubMed, Cureus)
    This study highlights the role of qPCR in the early detection of active CMV infections. Early diagnosis allows timely initiation of antiviral therapy and thereby improves clinical outcomes, particularly in immunocompromised individuals.
    Retrospective data • Journal
    |
    CD34 (CD34 molecule) • CD14 (CD14 Molecule)
    10d
    Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma. (PubMed, J Immunother Cancer)
    Our findings reveal regimen-specific systemic immune mechanisms in advanced HCC: Atez/Bev amplifies monocyte-NK cytotoxic axes, whereas Dur/Tre enhances monocyte-T cell inflammatory networks and TCR repertoire diversity. These insights highlight distinct predictive biomarkers and support regimen-tailored immunotherapy in HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PRKCH (Protein Kinase C Eta) • CD14 (CD14 Molecule) • HLA-E (Major Histocompatibility Complex, Class I, E)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    14d
    Spatial Immune Profiling and AI-Based Classifiers Identify Predictors of BCG Therapy Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer. (PubMed, Cancers (Basel))
    Spatial single-cell profiling and IMC-GA-MIL identify spatial immune and stromal features associated with BCG failure. However, findings from both analyses should be considered exploratory and will require validation in larger, independent cohorts.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD14 (CD14 Molecule) • CD68 (CD68 Molecule) • ITGAM (Integrin, alpha M) • FOXP3 (Forkhead Box P3)
    14d
    Targeting the Glutamine Transporter SLC1A5 Enhances Sensitivity of Acute Myeloid Leukemia to MLN4924. (PubMed, Biomedicines)
    Co-targeting neddylation and glutamine transporter SLC1A5 synergistically exerts anti-leukemic effects, at least in part through disruption of the TCA cycle. This combination represents a novel and effective therapeutic strategy against AML.
    Journal
    |
    SLC1A5 (Solute Carrier Family 1 Member 5) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M) • ANXA5 (Annexin A5)
    |
    pevonedistat (MLN4924)